Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2), which could inhibit VEGF-stimulated endothelial cell migration and proliferation, decrease tumor microvascular density, and block the formation of new blood vessels in tumor tissue [16]. Here, VEGFA is linked to neoplasm.